CN105476020A - Vitamin D3 soft capsule and preparation method thereof - Google Patents
Vitamin D3 soft capsule and preparation method thereof Download PDFInfo
- Publication number
- CN105476020A CN105476020A CN201510859340.4A CN201510859340A CN105476020A CN 105476020 A CN105476020 A CN 105476020A CN 201510859340 A CN201510859340 A CN 201510859340A CN 105476020 A CN105476020 A CN 105476020A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- soft capsule
- seed oil
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 104
- 239000007901 soft capsule Substances 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 235000005282 vitamin D3 Nutrition 0.000 title abstract 5
- 239000011647 vitamin D3 Substances 0.000 title abstract 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 title abstract 5
- 229940021056 vitamin d3 Drugs 0.000 title abstract 5
- 229940046008 vitamin d Drugs 0.000 claims abstract description 100
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 99
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 99
- 239000011710 vitamin D Substances 0.000 claims abstract description 99
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 99
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 23
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 22
- 239000003381 stabilizer Substances 0.000 claims abstract description 22
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 21
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims abstract description 21
- 239000001354 calcium citrate Substances 0.000 claims abstract description 21
- 229920000159 gelatin Polymers 0.000 claims abstract description 21
- 235000019322 gelatine Nutrition 0.000 claims abstract description 21
- 235000013337 tricalcium citrate Nutrition 0.000 claims abstract description 21
- 235000001014 amino acid Nutrition 0.000 claims abstract description 20
- 150000001413 amino acids Chemical class 0.000 claims abstract description 20
- 235000019498 Walnut oil Nutrition 0.000 claims abstract description 18
- 239000008170 walnut oil Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 11
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims abstract description 8
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 claims abstract description 6
- 241000208689 Eucommia ulmoides Species 0.000 claims abstract 6
- 238000003756 stirring Methods 0.000 claims description 35
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 108010010803 Gelatin Proteins 0.000 claims description 20
- 235000006708 antioxidants Nutrition 0.000 claims description 20
- 239000008273 gelatin Substances 0.000 claims description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 10
- 235000013871 bee wax Nutrition 0.000 claims description 10
- 239000012166 beeswax Substances 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 10
- 239000003292 glue Substances 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000006187 pill Substances 0.000 claims description 10
- 229940083466 soybean lecithin Drugs 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 9
- 235000019165 vitamin E Nutrition 0.000 claims description 9
- 239000011709 vitamin E Substances 0.000 claims description 9
- 229940046009 vitamin E Drugs 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000003921 oil Substances 0.000 claims description 7
- 235000019198 oils Nutrition 0.000 claims description 7
- 239000000084 colloidal system Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000009413 insulation Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 5
- 238000012545 processing Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 5
- 239000010935 stainless steel Substances 0.000 claims description 5
- 238000010792 warming Methods 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 11
- 229910052791 calcium Inorganic materials 0.000 abstract description 11
- 239000011575 calcium Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 10
- 239000011782 vitamin Substances 0.000 abstract description 10
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 229940088594 vitamin Drugs 0.000 abstract description 8
- 229930003231 vitamin Natural products 0.000 abstract description 8
- 235000013343 vitamin Nutrition 0.000 abstract description 8
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052698 phosphorus Inorganic materials 0.000 abstract description 7
- 239000011574 phosphorus Substances 0.000 abstract description 7
- 230000036737 immune function Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 3
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 230000003925 brain function Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract 2
- 239000001828 Gelatine Substances 0.000 abstract 1
- 235000014360 Punica granatum Nutrition 0.000 abstract 1
- 244000294611 Punica granatum Species 0.000 abstract 1
- MECHNRXZTMCUDQ-UHFFFAOYSA-N Vitamin D2 Natural products C1CCC2(C)C(C(C)C=CC(C)C(C)C)CCC2C1=CC=C1CC(O)CCC1=C MECHNRXZTMCUDQ-UHFFFAOYSA-N 0.000 abstract 1
- 210000000133 brain stem Anatomy 0.000 abstract 1
- 229960002061 ergocalciferol Drugs 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
- 235000001892 vitamin D2 Nutrition 0.000 abstract 1
- 239000011653 vitamin D2 Substances 0.000 abstract 1
- 238000003304 gavage Methods 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 12
- 244000237330 gutta percha tree Species 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 230000003203 everyday effect Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- CUXYLFPMQMFGPL-BGDVVUGTSA-N (9Z,11E,13Z)-octadecatrienoic acid Chemical group CCCC\C=C/C=C/C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-BGDVVUGTSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 235000021388 linseed oil Nutrition 0.000 description 4
- 239000000944 linseed oil Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 238000006303 photolysis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 2
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 208000007442 rickets Diseases 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- CUXYLFPMQMFGPL-UYWAGRGNSA-N trichosanic acid Natural products CCCCC=C/C=C/C=CCCCCCCCC(=O)O CUXYLFPMQMFGPL-UYWAGRGNSA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical group C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000251123 Mustelus antarcticus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003026 anti-oxygenic effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000015015 brainstem development Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002294 pubertal effect Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention belongs to the field of health food, and in particular relates to a vitamin D3 soft capsule and a preparation method thereof. The vitamin D3 soft capsule includes an internal contained substance and a capsule shell, the internal contained substance comprises the following components in parts by weight: vitamin D3, vitamin D2, walnut oil, eucommia ulmoides seed oil, pomegranate seed oil, amino acids, calcium citrate, an antioxidant and a stabilizer; and the capsule shell comprises the following components in parts by weight: gelatine, glycerol, titanium dioxide, and purified water. The vitamin D3 soft capsules contains a variety of vitamins and vegetable oils, can be used for supplement of a sufficient amount of vitamin D and promotion the absorption of calcium and phosphorus, can provide a variety of nutrients for the human body, and has the effects of enhancing brain function, enhance human immune function, promoting the development of the brain and nervous system, eliminating free radicals in the body, preventing a variety of chronic diseases, and the like.
Description
Technical field
The invention belongs to field of health care food, particularly relate to a kind of vitamin D
3soft capsule and preparation method thereof.
Background technology
Vitamin D
3be a kind of to the mankind and growth of animal, growth, breed, sustain life and ensure healthy indispensable liposoluble vitamin.Its Main Function regulates Ca,P metabolism, promotes absorption and the sclerotin calcification of calcium, phosphorus in field, maintain the balance of blood calcium and serium inorganic phosphorus.Vitamin D
3shortage can cause that rickets, osteomalacia, osteoporosis, thyroid gland technical ability go down etc. disease.Calendar year 2001 Du Xueqin, to the popularity investigation display of the vitamin D deficiency that 1248, Chinese Beijing area, 12 ~ 14 years old Pubertal girls carries out, has the people of 45.2% to be in the clinical deficiency state of vitamin D in the winter that sunshine is more weak.The ability of skin synthesis of vitamin d precursor declines gradually along with the stingy of age on the other hand, adds that the elderly decreases outdoor activity because mobility is limited, can infer that the shortage of vitamin D is generally deposited in healthy elderly.As can be seen here, vitamin d insufficiency is still common Problems existing.
Chinese patent application 201010032463.8 provides a kind of dimension D calcium soft capsule and preparation method thereof, and comprising: Paris white, vitamine D3, soybean salad oil, soybean lecithin, beeswax, this dimension D calcium soft capsule can supplement a certain amount of vitamin D
3and calcium, but the vitamin D of this dimension D calcium soft capsule
3content is few, poor stability, easy photodissociation, and its nutritional labeling is more single.
Therefore, be necessary to provide a kind of and have good stability, the vitamin D of not oxidizable, nutritional labeling diversification
3soft capsule.
Summary of the invention
The present invention, in order to make up the deficiencies in the prior art, provides a kind of nutritional labeling diversification, for human body supplement enough vitamin Ds while promote the absorption of calcium phosphorus, this vitamin D
3soft capsule has good stability, not oxidizable and photodissociation.Inventor, by the checking repeatedly of clinical practice, adjusts amount and the kind of each component, has finally invented the vitamin D of a nutritional labeling diversification
3soft capsule.
To achieve these goals, technical scheme of the present invention is as follows:
A kind of vitamin D
3soft capsule, comprises content and softgel shell, and described content comprises the component of following parts by weight: vitamin D
310 ~ 30 parts, vitamin D
21 ~ 6 part, walnut oil 3 ~ 10 parts, eucommia ulmoides seed oil 2 ~ 6 parts, granada seed oil 2 ~ 6 parts, 6 ~ 15 parts, amino acid, calcium citrate 0.5 ~ 3 part, antioxidant 3 ~ 6 parts and stabilizing agent 0.2 ~ 3 part; Described softgel shell comprises the component of following parts by weight: 25 ~ 50 parts, gelatin, glycerine 15 ~ 20 parts, titanium dioxide 2 ~ 3 parts and purified water 10 ~ 20 parts.
Preferably, described content comprises the component of following parts by weight: vitamin D
310 parts, vitamin D
21 part, walnut oil 3 parts, eucommia ulmoides seed oil 2 parts, granada seed oil 2 parts, 6 parts, amino acid, calcium citrate 1 part, antioxidant 3 parts and stabilizing agent 1 part.
Preferably, described content comprises the component of following parts by weight: vitamin D
320 parts, vitamin D
24 parts, walnut oil 6 parts, eucommia ulmoides seed oil 4 parts, granada seed oil 4 parts, 9 parts, amino acid, calcium citrate 2 parts, antioxidant 4.5 parts and stabilizing agent 2 parts.
Preferably, described content comprises the component of following parts by weight: vitamin D
330 parts, vitamin D
26 parts, walnut oil 10 parts, eucommia ulmoides seed oil 6 parts, granada seed oil 6 parts, amino acid/11 2 parts, calcium citrate 3 parts, antioxidant 6 parts and stabilizing agent 3 parts.
Preferably, described antioxidant is made up of by the weight ratio of 2 ~ 4:1 ~ 2 vitamin C and vitamin E.
Preferably, described stabilizing agent is selected from beeswax, suet and soybean lecithin.
Preferably, described amino acid is at least one in lysine, threonine, glutamic acid and isoleucine.
Preferably, described softgel shell also comprises iron oxide 1 ~ 3 part and anticorrisive agent 0.1 ~ 1 part.
Correspondingly, present invention also offers described vitamin D
3the preparation method of soft capsule, it comprises the following steps:
S1: take purified water and glycerine mixing and stirring in stainless-steel pan respectively, add described gelatin, temperature controls decompression at 30 ~ 40 DEG C and stirs, and is warming up to 50 ~ 80 DEG C, stirs and above-mentioned gelatin particle is dissolved completely after described gelatin expands; Add described titanium dioxide, decompression stirring makes it to dissolve completely evenly, filters, and filtrate 50 ~ 60 DEG C insulation leaves standstill, and obtains softgel shell glue, stand-by;
S2: take described stabilizing agent, antioxidant, vitamin D respectively
3and vitamin D
2, mixing and stirring; Add described walnut oil, eucommia ulmoides seed oil, granada seed oil, amino acid and calcium citrate, stir, cross colloid mill homogeneous 3 ~ 5 times, each homogeneous 15 ~ 30min, the i.e. suspension of obtained appearance uniform, is placed in material-compound tank and stirs 60 ~ 100min by suspension, i.e. obtained described content;
S3: control temperature is at 20 ~ 25 DEG C, by above-mentioned softgel shell glue and content automatic rotation pellet processing machine pill, it is 0.8 ~ 1.0mm that shell thickness controls, and washes away capsule and pill surface oil stain with ethanol, at 30 ~ 35 DEG C, drying 10 ~ 20 hours, packs and obtains described vitamine D3 soft capsule.
Preferably, in described S1 step, anticorrisive agent and iron oxide is added.
Vitamin D described in the present invention
3the absorption of human body to calcium, phosphorus can be improved, the level of plasma calcium and blood plasma phosphorus is reached capacity degree, growth promoting effects and bone calcification, promote that tooth perfects; Increased the absorption of phosphorus by intestines wall, and increase the absorption of phosphorus by renal tubule; Maintain the normal level of citrate in blood: prevent amino acid from being lost by kidney.For the control of rickets, malacosteon and infantile tetany.
Described walnut oil is rich in the multiple unsaturated acids up to about 90%, wherein linoleic acid content is more, for 3 to 4 times of common rapeseed oil content, especially eat with the crowd of applicable pregnant woman, infant, student, white collar and overwork of requiring mental skill, be called it is " melatonin " in food by numerous personages.
In described eucommia ulmoides seed oil, unsaturated fatty acid content is 91.18%, and aliphatic acid consists of leukotrienes 67.38%, linoleic acid 9.97%, oleic acid 15.81%, stearic acid 2.15%.Palmitic acid 4.68%, leukotrienes is main in vivo to be existed with the form of DHA and EPA.There is hypotensive, reducing blood lipid, raising memory and vision, promote that infant brain is grown, antiallergy, the function such as anticancer, antitumor, all have positive effect to enhancing memory function, analgesia, antifatigue, anti-ageing, antitumor, immunity moderation function etc., especially unique bidirectional modulation immunologic function is to safeguarding that the health of human body plays vital effect.
Described granada seed oil is the how unsaturated conjugated aliphatic acid of unique plant source, and its main component is punicic acid, and content can reach 70-80%.Because of the structure of punicic acid and CLA (CLA) the most close to and be referred to as " super CLA ", its functional CLA exceeded in general sense.Granada seed oil is also rich in Antioxidative Factors; the ability that there is very strong removing human free radical and delay senility; granada seed oil can protect human immune system; prevention of arterial is atherosis; reduce canceration, help human body opposing cancer, obesity, diabetes and heart disease, the ability that there is very strong removing human free radical He delay senility; also contain the plant female hormone similar to the female hormone structure that human body natural produces in granada seed oil simultaneously, contribute to alleviating women's climacteric syndrome.
Described calcium citrate is compared with calcium carbonate, calcium citrate does not need hydrochloric acid in gastric juice activated absorption, absorptivity is good, gaseous distention can not be caused in vivo as calcium carbonate produces carbon dioxide, harmless to alimentary canal mucous membrane, calcium citrate is to the even stronger complexing of calcium simultaneously, when the concentration of calcium citrate in vivo increases, it can in conjunction with free calcium ion, and the calcium of replacing in such as calcium oxalate, calcium phosphate, form stable complex compound soluble in water, discharge in body, inhibit calcium salt (calcium oxalate etc.) due to over-saturation state the lithogenous process of crystallize out shape.
Compared with prior art, the present invention has following technical advantage:
1, vitamin D provided by the invention
3soft capsule contains multivitamin and various plants oil, promote the absorption of calcium phosphorus while for human body vitamin D, and multiple nutritional components can be provided for human body, have and strengthen cerebral function, enhancing immune function of human body, promote brain and nervous system development, remove interior free yl, prevent the effects such as multiple chronic disease generation.
2, vitamin D provided by the invention
3soft capsule, as the outer used time, can also play whitening, moisturizing, crease-resistant effect.
3, vitamin D provided by the invention
3stability of Soft Capsules is good, has not easily photodissociation, not oxidizable advantage.
4, vitamin D of the present invention
3soft capsule preparation technology is simple, is convenient to industrial mass production.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following examples represents the technology playing good action in the practice of the invention of the present inventor's discovery.But, many changes can be made in disclosed specific embodiments, and still obtain same or analogous result, and not depart from the spirit and scope of the present invention.
Vitamin D described in the embodiment of the present invention
3in soft capsule, the information such as producer and article No. of constituent part is as follows:
Embodiment 1: vitamin D
3soft capsule.
The vitamin D of the embodiment of the present invention 1
3soft capsule comprises content and softgel shell, and described content comprises the component of following parts by weight: vitamin D
310 parts, vitamin D
21 part, walnut oil 3 parts, eucommia ulmoides seed oil 2 parts, granada seed oil 2 parts, 6 parts, amino acid, calcium citrate 1 part, antioxidant 3 parts and stabilizing agent 1 part; Described softgel shell comprises the component of following parts by weight: 25 parts, gelatin, glycerine 15 parts, titanium dioxide 2 parts and purified water 10 parts.
Wherein, described antioxidant is made up of Catergen part and vitamin e1 part, and described stabilizing agent is made up of 0.2 part, beeswax, suet 0.3 part and soybean lecithin 0.5 part.
Preparation method:
S1: get purified water and glycerine mixing and stirring in stainless-steel pan, add gelatin, temperature controls decompression at 30 DEG C and stirs, and is warming up to 60 DEG C, stirs and gelatin particle is dissolved completely after described gelatin expands; Add titanium dioxide, decompression stirring makes it to dissolve completely evenly, filters, and filtrate 50 DEG C insulation leaves standstill, and obtains softgel shell glue, stand-by;
S2: get beeswax, suet, soybean lecithin, vitamin C, vitamin E, vitamin D
3and vitamin D
2, mixing and stirring; Add described walnut oil, eucommia ulmoides seed oil, granada seed oil, amino acid and calcium citrate, stir, cross colloid mill homogeneous 3 times, each homogeneous 20min, namely the suspension of obtained appearance uniform, is placed in material-compound tank by suspension and stirs 60min, i.e. obtained described content;
S3: control temperature is at 20 DEG C, and by above-mentioned softgel shell glue and content automatic rotation pellet processing machine pill, shell thickness controls as 0.8mm, and wash away capsule and pill surface oil stain with ethanol, drying 15 hours, packs and obtain described vitamin D at 35 DEG C
3soft capsule.
Embodiment 2: vitamin D
3soft capsule.
The vitamin D of the embodiment of the present invention 2
3soft capsule comprises content and softgel shell, and described content comprises the component of following parts by weight: vitamin D
320 parts, vitamin D
24 parts, walnut oil 6 parts, eucommia ulmoides seed oil 4 parts, granada seed oil 4 parts, 9 parts, amino acid, calcium citrate 2 parts, antioxidant 4.5 parts and stabilizing agent 2 parts; Described softgel shell comprises the component of following parts by weight: 35 parts, gelatin, glycerine 15 parts, titanium dioxide 2 parts, iron oxide 2 parts, anticorrisive agent 0.5 part and purified water 15 parts.
Wherein, described antioxidant is made up of vitamin C 3 parts and vitamin e1 .5 part, and described stabilizing agent is made up of 0.5 part, beeswax, suet 0.5 part and soybean lecithin 1 part.
Preparation method:
S1: get above-mentioned purified water, glycerine, anticorrisive agent mixing and stirring in stainless-steel pan, add above-mentioned gelatin, temperature controls decompression at 36 DEG C and stirs, and is warming up to 60 DEG C, stirs and gelatin particle is dissolved completely after described gelatin expands; Add titanium dioxide and iron oxide, decompression stirring makes it to dissolve completely evenly, filters, and filtrate 55 DEG C insulation leaves standstill, and obtains softgel shell glue, stand-by;
S2: get above-mentioned beeswax, suet, soybean lecithin, vitamin C, vitamin E, vitamin D
3and vitamin D
2, mixing, stirs; Add described walnut oil, eucommia ulmoides seed oil, granada seed oil, amino acid and calcium citrate, stir, cross colloid mill homogeneous 4 times, each homogeneous 20min, namely the suspension of obtained appearance uniform, is then placed in material-compound tank by suspension and stirs 80min, i.e. obtained described content;
S3: control temperature is at 22 DEG C, and by above-mentioned softgel shell glue and content automatic rotation pellet processing machine pill, shell thickness controls as 0.9mm, washes away capsule and pill surface oil stain with ethanol, and drying 15 hours at 35 DEG C, packaging makes the vitamin D of 300mg/ grain
3soft capsule.
Embodiment 3: vitamin D
3soft capsule.
The vitamin D of the embodiment of the present invention 3
3soft capsule comprises content and softgel shell, and described content comprises the component of following parts by weight: vitamin D
330 parts, vitamin D
26 parts, walnut oil 10 parts, eucommia ulmoides seed oil 6 parts, granada seed oil 6 parts, amino acid/11 2 parts, calcium citrate 3 parts, antioxidant 6 parts and stabilizing agent 3 parts; Described softgel shell comprises the component of following parts by weight: 50 parts, gelatin, glycerine 20 parts, titanium dioxide 3 parts, iron oxide 3 parts, anticorrisive agent 1 part and purified water 20 parts.
Wherein, described antioxidant is made up of vitamin C 4 parts and vitamin E2 part, and described stabilizing agent is made up of 0.5 part, beeswax, suet 0.5 part and soybean lecithin 2 parts.
Preparation method:
S1: get above-mentioned purified water, glycerine, anticorrisive agent mixing and stirring in stainless-steel pan, add above-mentioned gelatin, temperature controls decompression at 40 DEG C and stirs, and is warming up to 80 DEG C, stirs and gelatin particle is dissolved completely after described gelatin expands; Add titanium dioxide and iron oxide, decompression stirring makes it to dissolve completely evenly, filters, and filtrate 60 DEG C insulation leaves standstill, and obtains softgel shell glue, stand-by;
S2: get above-mentioned beeswax, suet, soybean lecithin, vitamin C, vitamin E, vitamin D
3and vitamin D
2, mixing, stirs; Add described walnut oil, eucommia ulmoides seed oil, granada seed oil, amino acid and calcium citrate, stir, cross colloid mill homogeneous 5 times, each homogeneous 30min, namely the suspension of obtained appearance uniform, is then placed in material-compound tank by suspension and stirs 100min, i.e. obtained described content;
S3: control temperature is at 24 DEG C, and by above-mentioned softgel shell glue and content automatic rotation pellet processing machine pill, shell thickness controls as 1.0mm, washes away capsule and pill surface oil stain with ethanol, and drying 20 hours at 35 DEG C, packaging makes the vitamin D of 300mg/ grain
3soft capsule.
Comparative example 1: vitamin D
3soft capsule.
Described antioxidant is made up of vitamin C 1 part and vitamin E 3 parts, and all the other compositions are as embodiment 2.
Preparation method's reference example 2.
Comparative example 2: vitamin D
3soft capsule.
Described stabilizing agent is made up of 0.5 part, beeswax and soybean lecithin 1.5 parts, and all the other compositions are as embodiment 2.
Preparation method's reference example 2.
Stability test
1, trial drug and grouping
Embodiment 1 group: the embodiment of the present invention 1 vitamin D
3soft capsule;
Embodiment 2 groups: the embodiment of the present invention 2 vitamin D
3soft capsule;
Embodiment 3 groups: the embodiment of the present invention 3 vitamin D
3soft capsule;
Comparative example 1 group: comparative example 1 vitamin D of the present invention
3soft capsule;
Comparative example 2 groups: comparative example 2 vitamin D of the present invention
3soft capsule;
Control group: gummy shark vitamin D soft capsule.
2, test method
After above-described embodiment 1 ~ 3 group, comparative example 1 ~ 2 group and control group trial drug are placed 200 hours under the fluorescent lamp of 3000 luxs, use high performance liquid chromatograph, under following condition determination, obtain vitamin D in each group
3survival rate, utilize the postradiation soft capsule of visual relatively light with without the tone of light-struck soft capsule wafer, evaluate the stability of tone.
Survival rate condition determination
Device: Shimadzu Seisakusho Ltd. high performance liquid chromatograph (Autoinjector-SIL-10A, liquor charging unit LC-10AD, system controller SCL-10A, detector SPD-10A, post baking oven (columnoven) CTD-10A/10AC, ChromatopackC-R7Apuls); Post: Waters SymmetryC183.5um4.6 × 150mm; Sample size: 200 microlitres (sample solution concentration is about 125ng/ml); Column temperature: 25 DEG C; Mobile phase: acetonitrile: water: oxolane: acetic acid=1350:400:250:1(V/V); Flow velocity: 1ml/min; Detector: UV detector 265nm.
3, measurement result is as shown in table 1.
Table 1 survival rate measurement result
| Group | Vitamin D 3Survival rate (%) |
| Control group | 74.2 |
| Embodiment 1 group | 96.2 |
| Embodiment 2 groups | 98.1 |
| Embodiment 3 groups | 95.5 |
| Comparative example 1 group | 75.5 |
| Comparative example 2 groups | 70.1 |
4, conclusion.
As seen from the above table, the present embodiment 1 ~ 3 group of vitamin D
3the fluorescent lamp of soft capsule through 3000 luxs be after 200 hours, its survival rate all more than 90%, all far away higher than control group, wherein, with embodiment 2 groups of vitamin Ds
3the survival rate of soft capsule is the highest, reaches 98.1%, therefore embodiment 2 groups is preferred embodiment; Comparative example 1 group changes the amount ratio of vitamin C and vitamin E in antioxidant, and its survival rate is only 83.5%, is starkly lower than embodiment 1 ~ 3 group, therefore can learns, the amount comparison vitamin D of the present invention of vitamin C and vitamin E
3there is impact in the antioxygenic property of soft capsule; Comparative example 2 groups changes the kind composition of stabilizing agent, and its survival rate is also starkly lower than embodiment 1 ~ 3 group, as can be seen here, and vitamin D of the present invention
3the kind of soft capsule vitamin C and vitamin E, stabilizing agent is through lot of experiments and screens the optimised quantity ratio and kind that draw, therefore, and vitamin D of the present invention
3soft capsule has good stability, and it is photodissociation and oxidation not easily, and retention cycle is long.
In following test, because the stability of comparative example 1,2 groups is not good, therefore not it can be used as test target.
Test example one vitamin D of the present invention
3soft capsule is on the impact of mouse brain function
1, experimental animal and grouping
Choose healthy mice 50, male and female half and half, 19 ~ 25g, be divided into 5 groups at random, often organize 10, be respectively vitamin D of the present invention
3the high, medium and low dosage group of soft capsule, control group and model group.
2, medication
Embodiment 2 vitamin D
3soft capsule high dose group, gavage gives 45mg/kg; Every day gavage 1 time, continuous gavage 15 days;
Embodiment 2 vitamin D
3dosage group in soft capsule, gavage gives 22.5mg/kg; Every day gavage 1 time, continuous gavage 15 days;
Embodiment 2 vitamin D
3soft capsule low dose group, gavage gives 11.5mg/kg; , every day gavage 1 time, continuous gavage 15 days;
Control group: Kang man of great strength's linseed oil soft capsule, gavage gives 75mg/kg; Every day gavage 1 time, continuous gavage 15 days;
Model group: gavage gives isopyknic physiological saline (10ml.kg
-1); Every day gavage 1 time, continuous gavage 15 days.
3, test method
From administration the 16th day, after each administration 2 hours, mouse is put into reaction chamber endoadaptation environment 3 minutes, then be energized immediately, mouse is subject to galvanism, its normal reaction be rebound platform to hide noxious stimulation, each training 5 minutes, and record the number of times that every mouse shocked by electricity, in this, as school grade.Repeat above-mentioned test after 24 hours, namely this remember and keep test, jumps off the number of times (mistake sum) of irriate in incubation period and 3 minutes that record first time jumps off platform.
4, statistical analysis
Each group of test data adopts the process of SPSS17.0 software statistics, and compare employing variance analysis between many groups, P < 0.05 represents that difference has statistically significant meaning.
5, result of the test is as shown in table 2.
Table 2 test result (± S, n=10)
Note:
▲compared with model group, p<0.05;
▲ ▲compared with model group, p<0.01; * compared with control group, p<0.05.
6, conclusion
As shown in Table 2, successive administration is after 15 days, control group and the embodiment of the present invention 2 vitamin D
3the high, medium and low dosage group of soft capsule all can improve the learning and memory ability of mouse significantly, and has significant difference compared with model group; Wherein with the embodiment of the present invention 2 vitamin D
3the learning and memory ability of soft capsule high dose group mouse is best; Control group is Kang man of great strength's linseed oil soft capsule, and its main component comprises linseed oil, fish oil and wheat-germ oil, and it has raising cerebral function, strengthens brain activity, the effects such as develop immunitypty, the embodiment of the present invention 2 vitamin D
3soft capsule high dose group, compared with control group, all has significant difference p<0.05 in learning ability of mice and memory capability; As can be seen here, vitamin D of the present invention
3the effect of soft capsule in enhancing cerebral function is better than Kang man of great strength's linseed oil soft capsule, i.e. vitamin D of the present invention
3soft capsule has the effect strengthening cerebral function significantly, improve memory.
Test two vitamin Ds of the present invention
3soft capsule is on the impact of immune function of mice
1, experimental animal and grouping
Choose healthy mice 40, male and female half and half, 19 ~ 25g, be divided into 4 groups at random, often organize 10, be respectively vitamin D of the present invention
3the high, medium and low dosage group of soft capsule and control group.
2, medication
Embodiment 2 vitamin D
3soft capsule high dose group, gavage gives 45mg/kg; Every day gavage 1 time, continuous gavage 15 days;
Embodiment 2 vitamin D
3dosage group in soft capsule, gavage gives 22.5mg/kg; Every day gavage 1 time, continuous gavage 15 days;
Embodiment 2 vitamin D
3soft capsule low dose group, gavage gives 11.5mg/kg; , every day gavage 1 time, continuous gavage 15 days;
Model group: gavage gives isopyknic physiological saline (10ml.kg
-1); Every day gavage 1 time, continuous gavage 15 days.
3, test method
From administration the 16th day, after administration, 6 hours post-tensioning necks put to death mouse, take the weight (representing by organ weight/10g body weight) often organizing mouse thymus and spleen respectively.
4, statistical analysis
Each group of test data adopts the process of SPSS17.0 software statistics, and compare employing variance analysis between many groups, P < 0.05 represents that difference has statistically significant meaning.
5, result of the test is as shown in table 3.
Table 3 embodiment of the present invention 2 vitamin D
3soft capsule is on the impact (± S, n=10) of immune function of mice
| Group | N(only) | Dosage (mg/kg) | Thymic weight (mg/10g body weight) | Spleen gland weight (mg/10g body weight) |
| Model group | 10 | - | 27.52±10.36 | 57.34±22.65 |
| High dose group | 10 | 45 | 35.28±14.07 ▲▲ | 63.12±25.09 ▲▲ |
| Middle dosage group | 10 | 22.5 | 32.17±12.51 ▲▲ | 61.29±24.39 ▲▲ |
| Low dose group | 10 | 11.5 | 28.39±11.35 | 58.30±23.18 |
Note:
▲compared with model group, p<0.05;
▲ ▲compared with model group, p<0.01.
6, conclusion.
As shown in Table 3, successive administration is after 15 days, compared with model group, and the embodiment of the present invention 2 vitamin D
3high, middle group of soft capsule can improve the weight of immune organ significantly, and has significant difference compared with model group, wherein best with the effect of high dose group, with as can be seen here, and the embodiment of the present invention 2 vitamin D
3soft capsule has the effect significantly strengthening immune function of human body.
Owing to describing the present invention by above preferred embodiment, in spirit of the present invention and/or scope, any for replacement/of the present invention or combination implement the present invention, be all apparent for a person skilled in the art, and be included among the present invention.
Claims (10)
1. a vitamin D
3soft capsule, comprises content and softgel shell, it is characterized in that, described content comprises the component of following parts by weight: vitamin D
310 ~ 30 parts, vitamin D
21 ~ 6 part, walnut oil 3 ~ 10 parts, eucommia ulmoides seed oil 2 ~ 6 parts, granada seed oil 2 ~ 6 parts, 6 ~ 15 parts, amino acid, calcium citrate 0.5 ~ 3 part, antioxidant 3 ~ 6 parts and stabilizing agent 0.2 ~ 3 part; Described softgel shell comprises the component of following parts by weight: 25 ~ 50 parts, gelatin, glycerine 15 ~ 20 parts, titanium dioxide 2 ~ 3 parts and purified water 10 ~ 20 parts.
2. vitamin D as claimed in claim 1
3soft capsule, is characterized in that, described content comprises the component of following parts by weight: vitamin D
310 parts, vitamin D
21 part, walnut oil 3 parts, eucommia ulmoides seed oil 2 parts, granada seed oil 2 parts, 6 parts, amino acid, calcium citrate 1 part, antioxidant 3 parts and stabilizing agent 1 part.
3. vitamin D as claimed in claim 1
3soft capsule, is characterized in that, described content comprises the component of following parts by weight: vitamin D
320 parts, vitamin D
24 parts, walnut oil 6 parts, eucommia ulmoides seed oil 4 parts, granada seed oil 4 parts, 9 parts, amino acid, calcium citrate 2 parts, antioxidant 4.5 parts and stabilizing agent 2 parts.
4. vitamin D as claimed in claim 1
3soft capsule, is characterized in that, described content comprises the component of following parts by weight: vitamin D
330 parts, vitamin D
26 parts, walnut oil 10 parts, eucommia ulmoides seed oil 6 parts, granada seed oil 6 parts, amino acid/11 2 parts, calcium citrate 3 parts, antioxidant 6 parts and stabilizing agent 3 parts.
5. the vitamin D as described in any one of claim 1 ~ 4
3soft capsule, is characterized in that, described antioxidant is made up of by the weight ratio of 2 ~ 4:1 ~ 2 vitamin C and vitamin E.
6. the vitamin D as described in any one of claim 1 ~ 4
3soft capsule, is characterized in that, described stabilizing agent is selected from beeswax, suet and soybean lecithin.
7. the vitamin D as described in any one of claim 1 ~ 4
3soft capsule, is characterized in that, described amino acid is at least one in lysine, threonine, glutamic acid and isoleucine.
8. vitamin D as claimed in claim 1
3soft capsule, is characterized in that, described softgel shell also comprises iron oxide 1 ~ 3 part and anticorrisive agent 0.1 ~ 1 part.
9. the vitamin D as described in claim 1-7
3the preparation method of soft capsule, is characterized in that, comprises the following steps:
S1: take purified water and glycerine mixing and stirring in stainless-steel pan respectively, add described gelatin, temperature controls decompression at 30 ~ 40 DEG C and stirs, and is warming up to 50 ~ 80 DEG C, stirs and above-mentioned gelatin particle is dissolved completely after described gelatin expands; Add described titanium dioxide, decompression stirring makes it to dissolve completely evenly, filters, and filtrate 50 ~ 60 DEG C insulation leaves standstill, and obtains softgel shell glue, stand-by;
S2: take described stabilizing agent, antioxidant, vitamin D respectively
3and vitamin D
2, mixing and stirring; Add described walnut oil, eucommia ulmoides seed oil, granada seed oil, amino acid and calcium citrate, stir, cross colloid mill homogeneous 3 ~ 5 times, each homogeneous 15 ~ 30min, the i.e. suspension of obtained appearance uniform, is placed in material-compound tank and stirs 60 ~ 100min by suspension, i.e. obtained described content;
S3: control temperature is at 20 ~ 25 DEG C, and by above-mentioned softgel shell glue and content automatic rotation pellet processing machine pill, it is 0.8 ~ 1.0mm that shell thickness controls, wash away capsule and pill surface oil stain with ethanol, at 30 ~ 35 DEG C, drying 10 ~ 20 hours, packs and obtains described vitamin D
3soft capsule.
10. vitamin D as claimed in claim 9
3the preparation method of soft capsule, is characterized in that, in described S1 step, add anticorrisive agent and iron oxide.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510859340.4A CN105476020B (en) | 2015-11-30 | 2015-11-30 | A kind of vitamin D3Soft capsule and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510859340.4A CN105476020B (en) | 2015-11-30 | 2015-11-30 | A kind of vitamin D3Soft capsule and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105476020A true CN105476020A (en) | 2016-04-13 |
| CN105476020B CN105476020B (en) | 2018-05-15 |
Family
ID=55663592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510859340.4A Active CN105476020B (en) | 2015-11-30 | 2015-11-30 | A kind of vitamin D3Soft capsule and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105476020B (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387864A (en) * | 2016-08-18 | 2017-02-15 | 安士生物科技（中山）有限公司 | Bone density increasing health-care soft capsules and preparation method thereof |
| CN106723064A (en) * | 2016-12-13 | 2017-05-31 | 广州富诺健康科技股份有限公司 | A kind of vitamin D3Soft capsule and preparation method thereof |
| CN107495361A (en) * | 2017-06-22 | 2017-12-22 | 湖南知达医药科技有限公司 | A kind of composition of children water-adding zinc and vitamin and preparation method thereof |
| CN109464418A (en) * | 2018-12-26 | 2019-03-15 | 广东润源中天生物科技有限公司 | A kind of vitamin C-vitamin E soft capsule and preparation method thereof |
| CN109602020A (en) * | 2018-12-26 | 2019-04-12 | 广东润源中天生物科技有限公司 | A kind of vitamin K soft capsule and preparation method thereof |
| CN109662953A (en) * | 2019-02-18 | 2019-04-23 | 威海金思力生物科技股份有限公司 | A kind of vitamin D soft capsule and preparation method thereof |
| CN111602820A (en) * | 2020-05-28 | 2020-09-01 | 广州富诺营养科技有限公司 | Drop containing vitamin A and vitamin D and its preparation method |
| CN114468287A (en) * | 2021-12-31 | 2022-05-13 | 天津市元生泰科技有限公司 | Formula and preparation method of chelated calcium suitable for astronauts |
| WO2023038524A1 (en) * | 2021-09-10 | 2023-03-16 | Liposoma Health B.V. | Lipid formulations for the preparation of health ingredient-containing hot drinks |
Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5745415B2 (en) * | 1977-12-19 | 1982-09-28 | ||
| JPH0515691B2 (en) * | 1986-12-29 | 1993-03-02 | Asahi Kasei Kogyo Kk | |
| CN1286938A (en) * | 2000-08-29 | 2001-03-14 | 洪中怡 | Capsulized walnut-vegetable oil food and its production process |
| CN1371281A (en) * | 1999-08-31 | 2002-09-25 | 中外制药株式会社 | Soft capsules |
| CN1475213A (en) * | 2003-06-26 | 2004-02-18 | 新疆特丰药业股份有限公司 | Soyisoflavone soft capsule and its preparation technology |
| DE202006014985U1 (en) * | 2006-09-29 | 2006-11-30 | Dr. Willmar Schwabe Gmbh & Co. Kg | Composition, useful for improving skin- and bone condition, comprises fat oils from seeds of black nettle (Perilla frutescens), vitamin C, vitamin E, calcium, vitamin K1 and vitamin D3 |
| CN101278965A (en) * | 2008-05-26 | 2008-10-08 | 北京星昊医药股份有限公司 | Soft capsule of humifuse spurge and preparing method thereof |
| CN101647810A (en) * | 2009-09-04 | 2010-02-17 | 芜湖市诺康生物科技有限公司 | Liquid calcium soft capsule |
| CN102125581A (en) * | 2010-01-14 | 2011-07-20 | 哈尔滨顺亿堂医药生物科技开发有限公司 | Method for preparing vitamin D calcium soft capsules |
| CN102218072A (en) * | 2011-04-20 | 2011-10-19 | 昆明邦宇制药有限公司 | Pharmaceutical composition for treating calcium deficiency, and preparation thereof |
| CN103190615A (en) * | 2013-04-03 | 2013-07-10 | 上海春芝堂生物制品有限公司 | Liquid calcium soft capsules and preparation method thereof |
| CN103734694A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Calcium supplement health food and preparation method thereof |
| CN103784419A (en) * | 2012-10-31 | 2014-05-14 | 成都国弘医药有限公司 | Softgel containing calcitriol and preparation method |
| US20140356424A1 (en) * | 2013-05-31 | 2014-12-04 | Ems S.A. | Composition for treatment or reduction of symptoms related to premenstrual syndrome (pms), premenstrual disphoric disorder (pmdd), premenopause, menopause or female hormonal disorders, in a pharmaceutical composition containing said form, and process for producing said pharmaceutical form and use of said composition |
| CN104432102A (en) * | 2014-12-03 | 2015-03-25 | 安徽哈博药业有限公司 | Calcium vitamin D soft capsule |
-
2015
- 2015-11-30 CN CN201510859340.4A patent/CN105476020B/en active Active
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5745415B2 (en) * | 1977-12-19 | 1982-09-28 | ||
| JPH0515691B2 (en) * | 1986-12-29 | 1993-03-02 | Asahi Kasei Kogyo Kk | |
| CN1371281A (en) * | 1999-08-31 | 2002-09-25 | 中外制药株式会社 | Soft capsules |
| CN1286938A (en) * | 2000-08-29 | 2001-03-14 | 洪中怡 | Capsulized walnut-vegetable oil food and its production process |
| CN1475213A (en) * | 2003-06-26 | 2004-02-18 | 新疆特丰药业股份有限公司 | Soyisoflavone soft capsule and its preparation technology |
| DE202006014985U1 (en) * | 2006-09-29 | 2006-11-30 | Dr. Willmar Schwabe Gmbh & Co. Kg | Composition, useful for improving skin- and bone condition, comprises fat oils from seeds of black nettle (Perilla frutescens), vitamin C, vitamin E, calcium, vitamin K1 and vitamin D3 |
| CN101278965A (en) * | 2008-05-26 | 2008-10-08 | 北京星昊医药股份有限公司 | Soft capsule of humifuse spurge and preparing method thereof |
| CN101647810A (en) * | 2009-09-04 | 2010-02-17 | 芜湖市诺康生物科技有限公司 | Liquid calcium soft capsule |
| CN102125581A (en) * | 2010-01-14 | 2011-07-20 | 哈尔滨顺亿堂医药生物科技开发有限公司 | Method for preparing vitamin D calcium soft capsules |
| CN102218072A (en) * | 2011-04-20 | 2011-10-19 | 昆明邦宇制药有限公司 | Pharmaceutical composition for treating calcium deficiency, and preparation thereof |
| CN103784419A (en) * | 2012-10-31 | 2014-05-14 | 成都国弘医药有限公司 | Softgel containing calcitriol and preparation method |
| CN103190615A (en) * | 2013-04-03 | 2013-07-10 | 上海春芝堂生物制品有限公司 | Liquid calcium soft capsules and preparation method thereof |
| US20140356424A1 (en) * | 2013-05-31 | 2014-12-04 | Ems S.A. | Composition for treatment or reduction of symptoms related to premenstrual syndrome (pms), premenstrual disphoric disorder (pmdd), premenopause, menopause or female hormonal disorders, in a pharmaceutical composition containing said form, and process for producing said pharmaceutical form and use of said composition |
| CN103734694A (en) * | 2013-11-21 | 2014-04-23 | 荣成百合生物技术有限公司 | Calcium supplement health food and preparation method thereof |
| CN104432102A (en) * | 2014-12-03 | 2015-03-25 | 安徽哈博药业有限公司 | Calcium vitamin D soft capsule |
Non-Patent Citations (2)
| Title |
|---|
| 卢耀勤等: "葡萄精华软胶囊的制备工艺研究", 《新疆医科大学学报》 * |
| 葛颖华； 钟晓明: "维生素C和维生素E抗氧化机制及其应用的研究进展", 《吉林医学》 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106387864A (en) * | 2016-08-18 | 2017-02-15 | 安士生物科技（中山）有限公司 | Bone density increasing health-care soft capsules and preparation method thereof |
| CN106723064A (en) * | 2016-12-13 | 2017-05-31 | 广州富诺健康科技股份有限公司 | A kind of vitamin D3Soft capsule and preparation method thereof |
| CN107495361A (en) * | 2017-06-22 | 2017-12-22 | 湖南知达医药科技有限公司 | A kind of composition of children water-adding zinc and vitamin and preparation method thereof |
| CN109464418A (en) * | 2018-12-26 | 2019-03-15 | 广东润源中天生物科技有限公司 | A kind of vitamin C-vitamin E soft capsule and preparation method thereof |
| CN109602020A (en) * | 2018-12-26 | 2019-04-12 | 广东润源中天生物科技有限公司 | A kind of vitamin K soft capsule and preparation method thereof |
| CN109662953A (en) * | 2019-02-18 | 2019-04-23 | 威海金思力生物科技股份有限公司 | A kind of vitamin D soft capsule and preparation method thereof |
| CN111602820A (en) * | 2020-05-28 | 2020-09-01 | 广州富诺营养科技有限公司 | Drop containing vitamin A and vitamin D and its preparation method |
| WO2023038524A1 (en) * | 2021-09-10 | 2023-03-16 | Liposoma Health B.V. | Lipid formulations for the preparation of health ingredient-containing hot drinks |
| NL2029172B1 (en) * | 2021-09-10 | 2023-03-21 | Liposoma Health B V | Lipid formulations for the preparation of health ingredient-containing hot drinks |
| CN114468287A (en) * | 2021-12-31 | 2022-05-13 | 天津市元生泰科技有限公司 | Formula and preparation method of chelated calcium suitable for astronauts |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105476020B (en) | 2018-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105476020A (en) | Vitamin D3 soft capsule and preparation method thereof | |
| JP7265787B2 (en) | Methods, compositions, and devices for meeting dietary fatty acid requirements | |
| CN110742267B (en) | Total-nutrient formula food for inflammatory bowel diseases | |
| CN104116078A (en) | Peony seed oil health product with functions of stabilizing blood pressure and reducing blood fat |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 510000 Guangdong city of Guangzhou province Haizhuqu District Chang Gang Road No. 238, room 2511 International Center of dart Applicant after: GUANGZHOU FUNUO HEALTH TECHNOLOGY CO.,LTD. Address before: 510000 Guangdong city of Guangzhou province Haizhuqu District Chang Gang Road No. 238, room 2511 International Center of dart Applicant before: GUANGZHOU FUNUO BIOTECHNOLOGY Co.,Ltd. |
|
| COR | Change of bibliographic data | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 3 / F, North Funuo health building, Yulu Avenue, Lankao County, Kaifeng City, Henan Province Patentee after: Funo health Co.,Ltd. Address before: 3 / F, North Funuo health building, Yulu Avenue, Lankao County, Kaifeng City, Henan Province Patentee before: Funo health (Lankao) Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP03 | Change of name, title or address |
Address after: 3 / F, North Funuo health building, Yulu Avenue, Lankao County, Kaifeng City, Henan Province Patentee after: Funo health (Lankao) Co.,Ltd. Address before: 510000, Guangdong Province, Haizhuqu District, Guangzhou Province, 238 Middle Road, Chang Yi dart International Center, room 2511 Patentee before: GUANGZHOU FUNUO HEALTH TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address |